pharma · Acute Myeloid Leukemia · Narcolepsy · JAZZ
Jazz Pharmaceuticals Ireland Limited
Jazz Pharmaceuticals Ireland is a pharma organization headquartered in Dublin, IE. It trades on NYSE under ticker JAZZ. Primary therapeutic focus areas include Acute Myeloid Leukemia, Narcolepsy, Epilepsy, Acute Lymphobl
Phase 2 · small molecule · Meningioma
JZP3507 is a small-molecule therapeutic candidate developed by Jazz Pharmaceuticals Ireland Limited for the treatment of meningioma, currently in Phase 2 clinical development. The program, identified by internal code JZP3507-202, represents Jazz's approach to addressing this rare brain tumor indication. As of April 202
Internal code JZP3507-202
JZP3507 is a small-molecule therapeutic candidate developed by Jazz Pharmaceuticals Ireland Limited for the treatment of meningioma, currently in Phase 2 clinical development. The program, identified by internal code JZP3507-202, represents Jazz's approach to addressing this rare brain tumor indication. As of April 2026, the program remains active with an ongoing Phase 2 trial (NCT07533942). The mechanism of action, specific molecular target, and detailed clinical efficacy data have not yet been disclosed. Jazz Pharmaceuticals' strategy appears focused on expanding its oncology portfolio into the meningioma space, where treatment options remain limited. The company has not disclosed projected peak sales, regulatory timelines, or partnership arrangements for this program. Key development milestones and regulatory interactions remain proprietary at this stage of development.
Meningioma represents a significant unmet medical need in neuro-oncology. These tumors, arising from the meninges surrounding the brain and spinal cord, account for approximately 30% of all primary brain tumors but have limited pharmacological treatment options beyond surgery and radiation. Many patients experience recurrence or progression, particularly in atypical or malignant subtypes, creating demand for effective systemic therapies. The meningioma market remains underserved compared to other CNS malignancies, with few approved targeted agents specifically indicated for this disease.
JZP3507 enters a competitive but relatively sparse therapeutic landscape. The Phase 2 status indicates the program has advanced beyond early-stage development, suggesting preliminary evidence of activity or safety warranting further investigation. Jazz Pharmaceuticals' entry into meningioma treatment aligns with broader industry interest in rare CNS tumors. Success in this indication could establish a differentiated position for Jazz within the neuro-oncology space and address a patient population with limited alternatives. The commercial significance depends on efficacy data, safety profile, and regulatory pathway clarity—factors not yet publicly detailed.
JZP3507 is a small-molecule therapeutic candidate. The specific mechanism of action, molecular target, and route of administration have not been disclosed. As a small-molecule modality in oncology development, JZP3507 is likely an oral or intravenous agent, though this remains unconfirmed. Related Jazz Pharmaceuticals programs in meningioma include ONC201, also a small-molecule in Phase 2 development for this indication, suggesting the company may be pursuing parallel or complementary approaches to meningioma treatment.
Also known as: meningioma (disease), meningothelial cell tumour, primary meningeal tumour
Prevalence: Annual incidence: 1-9 / 100 000 (Germany) — source: Orphanet, validated.
A generally slow growing tumor attached to the dura mater. It is composed of neoplastic meningothelial (arachnoidal) cells. It typically occurs in adults, often women and it has a wide range of histopathological appearances. Of the various subtypes, meningothelial, fibrous and transitional meningiomas are the most common. Most meningiomas are WHO grade I tumors, and some are WHO grade II or III tumors. Most subtypes share a common clinical behavior, although some subtypes are more likely to recur and follow a more aggressive clinical course. (Adapted from WHO)
ClinicalTrials.gov lists 112 registered studies for Meningioma (AACT aggregate).
Phase breakdown: NA (63), PHASE2 (25), PHASE1/PHASE2 (8), EARLY_PHASE1 (5), PHASE1 (5), PHASE3 (3), PHASE4 (3)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0016642), Orphanet — meningioma, NCT00003483, NCT00004483, NCT00589784, NCT00706810, NCT00859040, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 initiation
JZP3507-202 Phase 2 trial (NCT07533942) initiated; specific enrollment and start dates not yet disclosed.
Latest program milestone
Program remains active as of April 16, 2026; specific milestone details not yet disclosed.
Next expected milestone
Timing and nature of next clinical or regulatory milestone not yet disclosed.
JZP3507 competes within a limited but emerging meningioma therapeutic landscape. Jazz Pharmaceuticals itself is pursuing a parallel approach with ONC201, a small-molecule Phase 2 candidate also targeting meningioma, indicating the company's commitment to multiple mechanistic approaches in this indication. Heron Therapeutics is advancing B10 L-BPA Injection, a small-molecule Phase 2 program, representing an alternative modality or target strategy. Ningbo Cancer Hospital is conducting the EORTC 2334-BTG trial, a small-molecule Phase 2 study, reflecting international research efforts in meningioma treatment. Istituto Gentili S.r.l. is evaluating Stivarga (regorafenib) 40 mg film-coated tablets in Phase 2, representing a repurposed kinase inhibitor approach. The competitive field remains relatively sparse, suggesting limited head-to-head clinical data and differentiation opportunities for successful programs. JZP3507's competitive position depends on undisclosed efficacy, safety, and tolerability advantages relative to these alternatives.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| B10 L-BPA Injection | Heron Therapeutics | small_molecule | phase_2 |
| EORTC 2334-BTG | Ningbo Cancer Hospital | small_molecule | phase_2 |
| ONC201 | Jazz Pharmaceuticals Ireland Limited | small_molecule | phase_2 |
| Stivarga 40 mg film-coated tablets | Istituto Gentili S.r.l. | small_molecule | phase_2 |
| TRANEXAMIC ACID | — | Plasminogen inhibitor | Phase 3 |
| MIFEPRISTONE | — | Progesterone receptor antagonist | Phase 3 |
| VISTUSERTIB | — | Serine/threonine-protein kinase mTOR inhibitor | Phase 2 |
| VISMODEGIB | — | Smoothened homolog inhibitor | Phase 2 |
| REGORAFENIB | — | Fibroblast growth factor receptor 1 inhibitor | Phase 2 |
| PEMBROLIZUMAB | — | Programmed cell death protein 1 inhibitor | Phase 2 |
| PASIREOTIDE | — | Somatostatin receptor 1 agonist | Phase 2 |
| OCTREOTIDE | — | Somatostatin receptor agonist | Phase 2 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 2 |
| LUTETIUM OXODOTREOTIDE LU-177 | — | Somatostatin receptor binding agent | Phase 2 |
| LUTETIUM OXODOTREOTIDE | — | Somatostatin receptor binding agent | Phase 2 |
| IRINOTECAN HYDROCHLORIDE | — | DNA topoisomerase I inhibitor | Phase 2 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
Regulatory status for JZP3507 across major jurisdictions has not been disclosed. FDA, EMA, PMDA (Japan), and NMPA (China) interactions, breakthrough therapy designations, orphan drug status, or other regulatory pathways remain unknown. The program's Phase 2 status suggests it has not yet filed for regulatory approval in any jurisdiction. Meningioma's rare disease status may qualify JZP3507 for expedited regulatory pathways or orphan drug designations, but such designations have not been publicly announced. Future regulatory milestones, including Phase 3 initiation timelines or anticipated approval discussions, are not yet disclosed.
JZP3507 is a small-molecule therapeutic candidate in Phase 2 development for the treatment of meningioma, a rare brain tumor arising from the meninges surrounding the brain and spinal cord.
JZP3507 is developed and sponsored by Jazz Pharmaceuticals Ireland Limited. No manufacturing partners or licensees have been disclosed.
No. JZP3507 is currently in Phase 2 clinical development and has not been approved by the FDA or any other regulatory authority.
The mechanism of action and molecular target of JZP3507 have not been disclosed by Jazz Pharmaceuticals.
The route of administration (oral, intravenous, or other) has not been disclosed.
JZP3507 is being evaluated in the Phase 2 trial NCT07533942 (JZP3507-202). Specific trial design details and enrollment information have not been disclosed.
The timing of Phase 2 data release has not been disclosed. Clinical trial results are not yet reported.
Competing Phase 2 meningioma programs include ONC201 (Jazz Pharmaceuticals), B10 L-BPA Injection (Heron Therapeutics), EORTC 2334-BTG (Ningbo Cancer Hospital), and Stivarga (Istituto Gentili S.r.l.).
Orphan drug designation status for JZP3507 has not been disclosed.
No partnership or licensing arrangements for JZP3507 have been disclosed. The program is solely sponsored by Jazz Pharmaceuticals Ireland Limited.
Meningioma lacks effective systemic pharmacological treatments, with limited options beyond surgery and radiation. Recurrent and atypical meningiomas particularly lack targeted therapies, creating significant unmet medical need.
No approval timeline has been disclosed. The program is in Phase 2, and regulatory approval timelines are not yet publicly available.
JZP3507 targets patients with meningioma. Specific patient subsets (newly diagnosed, recurrent, atypical, malignant) have not been disclosed.
Yes. Jazz Pharmaceuticals is also developing ONC201, a small-molecule Phase 2 candidate for meningioma, indicating a multi-program approach to this indication.
JZP3507 is a small-molecule therapeutic candidate.
Breakthrough therapy designation status for JZP3507 has not been disclosed.
JZP3507 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Jazz Pharmaceuticals' pursuit of JZP3507 alongside ONC201 in meningioma suggests a portfolio approach to this underserved indication, potentially hedging against single-program risk. The company appears committed to establishing a meningioma franchise despite limited public disclosure of mechanism or clinical rationale.
Competitive Implications: The meningioma market remains fragmented with no dominant player. JZP3507's success would depend on demonstrating superiority or complementary benefits versus ONC201, B10 L-BPA, and other Phase 2 candidates. Limited competitive data makes differentiation assessment premature.
Future Catalysts: Key catalysts include Phase 2 efficacy and safety data release, potential Phase 3 initiation announcement, regulatory pathway clarification (orphan drug or breakthrough designation), and comparative clinical evidence versus competing programs. Timing of these milestones remains undisclosed.
Expected Milestones: Anticipated near-term catalysts include Phase 2 interim or final data presentations at oncology conferences, regulatory interactions regarding Phase 3 trial design, and potential partnership or licensing announcements. No specific dates have been disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.